The prescribing information for Adzynma, the only approved enzyme replacement therapy for an ultra-rare and potentially fatal clotting disorder, now carries the FDA's most serious form of warning. The label states that neutralizing antibodies against ADAMTS13, with serious outcomes including death, have been reported in patients treated with the drug.
The warning arrived through an unusual route. Federal documents show the agency and the manufacturer could not agree on the language, and the FDA ultimately issued a formal order compelling the change.
For the small number of American families managing congenital thrombotic thrombocytopenic purpura, the practical consequence is concrete. Every patient on the drug, including those who were doing well, now falls under a monitoring requirement that did not previously apply in this form.
A Warning the Company Did Not Want in That Form
The sequence is documented in an FDA safety labeling change order issued in May of this year. The agency first notified Takeda in February that it intended to require label changes covering neutralizing antibodies associated with serious outcomes including death.
Takeda responded the following month with a prior approval supplement proposing its own version. Discussions ran through the spring, with the agency sending modified language on three separate occasions and the company submitting two rounds of amendments.
The two sides did not reach agreement. The FDA concluded that the company's proposed changes did not adequately address the new safety information and, acting under its statutory authority, ordered Takeda to add a boxed warning and revise two additional sections of the label. The agency also required two postmarketing studies: a prospective multicenter interventional trial assessing immunogenicity and clinical loss of effectiveness, and a noninterventional real-world safety study following patients for at least a year after starting treatment.
The updated prescribing information now instructs clinicians to "monitor all patients closely for ADAMTS13 activity and development of ADAMTS13 neutralizing antibodies." That monitoring is specified both before starting the drug and periodically during treatment.
None of this establishes that the drug caused the reported death. When the FDA first disclosed its investigation, Takeda said its own assessment found "no confirmed causal relationship" between the medicine and the patient's death.
Antibodies That Can Silence a Replacement Enzyme
Congenital thrombotic thrombocytopenic purpura is caused by a deficiency in ADAMTS13, an enzyme that breaks down oversized clotting proteins. Without it, platelets clump abnormally and form small clots throughout the bloodstream, damaging organs. Estimates of how common the inherited form is vary widely, but genetic analysis of the disorder puts the commonly cited prevalence at roughly 0.5 to 2 people per million.
Adzynma works by supplying a laboratory-made version of the missing enzyme. The problem the warning describes is that the immune system can learn to recognize that replacement protein as foreign and produce antibodies that neutralize it.
Two things make this particularly difficult. First, when neutralizing antibodies develop, they can reduce or eliminate the response not only to Adzynma but also to plasma-derived ADAMTS13, potentially narrowing a patient's options. Second, current laboratory tests cannot distinguish between antibodies directed against the drug, a patient's own residual enzyme, or ADAMTS13 from other plasma sources.
The revised label is also explicit about what the clinical trials did and did not show. No patients in the company's studies tested positive for neutralizing antibodies. All of those participants had previously been exposed to ADAMTS13 through plasma-based products, and there are no immunogenicity data for patients who have never received plasma-based therapy. The signal emerged only after the product reached the market, through postmarketing adverse event reports rather than a controlled study.
That distinction is central to how drug safety works for such rare conditions. A trial enrolling a few dozen patients cannot reliably detect a complication occurring in a small fraction of them, which is why the FDA product page for the therapy continues to collect and post safety information after approval. The agency first disclosed its investigation into the reported death in November of last year.
Monitoring Now Applies to Every Patient on the Drug
The most immediate change for treating physicians is scope. The label directs monitoring of all patients, including both those previously exposed to plasma products and those who are treatment-naive, with ADAMTS13 activity and antibody testing before starting and at intervals during treatment.
The label further instructs that if expected enzyme activity levels are not reached or if an acute episode occurs despite appropriate dosing, clinicians should order an assay to measure neutralizing antibody concentrations.
That translates into more blood draws, more specialized laboratory testing, and more coordination for patients who are often managed at academic centers far from home. Specialized ADAMTS13 antibody assays are not routinely available at community hospitals, which can mean sending tests out and facing longer turnaround times.
Patient-facing language in the package insert now warns that inhibitors may stop the medicine from working properly and may be life-threatening, notes that serious side effects, including death, have been reported, and directs patients to confirm with their provider that they are being monitored with blood tests.
Families Managing an Ultra Rare Diagnosis Bear the Follow-Up
Because the inherited form of the disorder typically appears in childhood, as described in a clinical review of the condition, many affected households include a parent coordinating care for a child, sometimes across several siblings. Additional monitoring visits fall on those families in the form of missed school and work, travel to specialty centers, and repeated insurance authorizations for uncommon laboratory tests.
Patients should not stop or change infusions on their own. Untreated congenital TTP carries a high mortality risk, and abrupt discontinuation is its own danger. The appropriate step is to schedule a conversation with the hematology team to confirm whether antibody testing has been done and when the next check is due.
Anyone experiencing new neurological symptoms, unusual bruising, unexplained fatigue, or an episode that resembles a previous TTP flare should contact their treating team promptly rather than waiting for a routine appointment. Families can also ask whether their center has access to a laboratory that performs the specific neutralizing antibody assay, since availability varies and turnaround can affect how quickly a treatment decision gets made.
What remains unresolved is how often neutralizing antibodies actually develop. The two required postmarketing studies are designed to answer that question, and until results emerge, the true frequency remains unknown.
Key Questions Answered
What is the new warning about? The label now carries a boxed warning stating that neutralizing antibodies against ADAMTS13, with serious outcomes including death, have been reported in patients treated with Adzynma. These antibodies can reduce or eliminate the drug's effect.
Why is the process behind this warning notable? The FDA and Takeda exchanged proposed language for months without agreement. The agency then issued a formal order requiring the boxed warning, additional label revisions, and two postmarketing studies.
Has the drug been shown to cause deaths? Causation has not been established. The FDA said one reported death appeared related to the drug, while Takeda stated its own review found no confirmed causal relationship.
Who does this affect? Adults and children with congenital thrombotic thrombocytopenic purpura, an inherited disorder with a commonly cited prevalence of roughly 0.5 to 2 people per million, who receive Adzynma as preventive or on-demand therapy.
Should patients stop taking Adzynma? No one should stop or change infusions without speaking to their hematology team. Untreated congenital TTP carries a high risk of severe complications.
What monitoring is now required? The label directs testing of ADAMTS13 activity and neutralizing antibodies in all patients before starting treatment and periodically during it, with additional antibody testing if expected activity levels are not reached.
What is still unknown? How frequently neutralizing antibodies develop remains unmeasured. Two required postmarketing studies are intended to characterize that risk, and no results have been released.
